Literature DB >> 21122530

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.

Matthieu Allez1, Konstantinos Karmiris, Edouard Louis, Gert Van Assche, Shomron Ben-Horin, Amir Klein, Janneke Van der Woude, Filip Baert, Rami Eliakim, Konstantinos Katsanos, Jørn Brynskov, Flavio Steinwurz, Silvio Danese, Severine Vermeire, Jean-Luc Teillaud, Marc Lémann, Yehuda Chowers.   

Abstract

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.
Copyright © 2010 European Crohn's and Colitis Organisation. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122530     DOI: 10.1016/j.crohns.2010.04.004

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  75 in total

1.  IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.

Authors:  Lyssia Belarif; Richard Danger; Laetitia Kermarrec; Véronique Nerrière-Daguin; Sabrina Pengam; Tony Durand; Caroline Mary; Elise Kerdreux; Vanessa Gauttier; Aneta Kucik; Virginie Thepenier; Jerome C Martin; Christie Chang; Adeeb Rahman; Nina Salabert-Le Guen; Cécile Braudeau; Ahmed Abidi; Grégoire David; Florent Malard; Celine Takoudju; Bernard Martinet; Nathalie Gérard; Isabelle Neveu; Michel Neunlist; Emmanuel Coron; Thomas T MacDonald; Pierre Desreumaux; Hoa-Le Mai; Stephanie Le Bas-Bernardet; Jean-François Mosnier; Miriam Merad; Régis Josien; Sophie Brouard; Jean-Paul Soulillou; Gilles Blancho; Arnaud Bourreille; Philippe Naveilhan; Bernard Vanhove; Nicolas Poirier
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

2.  Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

Authors:  Carlos Taxonera; Manuel Barreiro-de Acosta; Marta Calvo; Cristina Saro; Guillermo Bastida; María D Martín-Arranz; Javier P Gisbert; Valle García-Sánchez; Ignacio Marín-Jiménez; Fernando Bermejo; María Chaparro; Ángel Ponferrada; María P Martínez-Montiel; Ramón Pajares; Celia de Gracia; David Olivares; Cristina Alba; Juan L Mendoza; Ignacio Fernández-Blanco
Journal:  Dig Dis Sci       Date:  2015-06-05       Impact factor: 3.199

3.  CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's Disease.

Authors:  Shrinivas Bishu; Mohammed El Zaatari; Atsushi Hayashi; Guoqing Hou; Nicole Bowers; Jami Kinnucan; Beth Manoogian; Michelle Muza-Moons; Min Zhang; Helmut Grasberger; Charlie Bourque; Weiping Zou; Peter D R Higgins; Jason R Spence; Ryan W Stidham; Nobuhiko Kamada; John Y Kao
Journal:  J Crohns Colitis       Date:  2019-07-25       Impact factor: 9.071

4.  The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

Authors:  A N Ananthakrishnan; A Sakuraba; E L Barnes; J Pekow; L Raffals; M D Long; R S Sandler
Journal:  Aliment Pharmacol Ther       Date:  2017-05-03       Impact factor: 8.171

5.  Improving IBD Care: A Personalized Approach to Management.

Authors:  Stephen B Hanauer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 6.  Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.

Authors:  Jørgen Jahnsen
Journal:  Therap Adv Gastroenterol       Date:  2016-03-21       Impact factor: 4.409

7.  Cholinergic Anti-Inflammatory Pathway Does Not Contribute to Prevention of Ulcerative Colitis by Novel Indoline Carbamates.

Authors:  Helena Shifrin; Odelia Mouhadeb; Nathan Gluck; Chen Varol; Marta Weinstock
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-07       Impact factor: 4.147

8.  Development of a Recombinant Xenogeneic Tumor Necrosis Factor Alpha Protein Vaccine To Protect Mice from Experimental Colitis.

Authors:  Yang Wan; Meng Li; Hailong Zhang; Xiuran Zheng; Chaoheng Yu; Gu He; Yan Luo; Li Yang; Yuquan Wei
Journal:  Clin Vaccine Immunol       Date:  2015-10-14

9.  Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.

Authors:  Edward Shelton; Jessica R Allegretti; Betsy Stevens; Matthew Lucci; Hamed Khalili; Deanna D Nguyen; Jenny Sauk; Cosmas Giallourakis; John Garber; Matthew J Hamilton; Michal Tomczak; Fredrick Makrauer; Robert B Burakoff; Jonathan Levine; Punyaganie de Silva; Sonia Friedman; Ashwin Ananthakrishnan; Joshua R Korzenik; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

10.  Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways.

Authors:  Jay Luther; Manish Gala; Suraj J Patel; Maneesh Dave; Nynke Borren; Ramnik J Xavier; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2018-01-25       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.